Navigation Links
Auxilium Pharmaceuticals to Announce Third Quarter 2012 Results and Conduct Conference Call on Wednesday, November 7, 2012
Date:11/1/2012

MALVERN, Pa., Nov. 1, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the third quarter 2012 on Wednesday, November 7, 2012 before the opening of the U.S. financial markets. The Company will also conduct a conference call that day at 10:00 a.m. ET to discuss results and highlights of the third quarter 2012.  The presentation slides to be used during the call will be available on the "For Investors" section of the Company's web site under the "Presentations" tab beginning at 10 a.m. ET on Wednesday, November 7, 2012.  A web cast of the conference call and the presentation slides will be available on the "For Investors" section of the Company's web site under the "Events" tab beginning at 10:00 a.m. ET on Wednesday, November 7, 2012.  A question and answer session will follow the presentation.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO

Mr. Adrian Adams, Chief Executive Officer and President, will host the conference call.Conference call details:Date:Wednesday, November 7, 2012Time:10:00 a.m. ETDial-in (U.S.):(888) 895-5271 Dial-in (International):(847) 619-6547Web cast:http://www.auxilium.com Passcode:AUXILIUMTo access an audio replay of the call:Access number (U.S.):(888) 843-7419Access number (International):(630) 652-3042Replay Passcode #:33615316About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical treatment of hypogonadism and XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord in the U.S. GSK co-promotes Testim with Auxilium in the U.S.  Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada.  Pfizer has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia; Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico.  An sBLA for XIAFLEX for the treatment of Peyronie's disease is expected to be submitted to the FDA by year end 2012.  Additionally, collagenase clostridium histolyticum ("CCH") is in phase IIa of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue additional indications for CCH. For additional information, visit http://www.auxilium.com

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to announce the third quarter 2012 results; and products in development for Peyronie's disease, including the expected filing of an sBLA, Frozen Shoulder syndrome and cellulite.  Forward-looking statements often address Auxilium's expected future financial position or business strategy and plans and objectives of management for future operations. Forward-looking statements provide Auxilium's current expectations or forecasts of future events. Auxilium's performance and financial results could differ materially from those reflected in these forward-looking statements due to various risks and uncertainties.  A more detailed list and description of the risks and uncertainties that Auxilium faces may be found under the heading "Risk Factors" in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, which are on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of the forward-looking statements contained in this release may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Auxilium undertakes no obligation to update publicly any forward-looking statement.AUXILIUM CONTACTS: James E. Fickenscher / CFO

William Q. Sargent, Jr. / V.P., IR  Auxilium Pharmaceuticals, Inc.

Auxilium Pharmaceuticals, Inc.(484) 321-5900

(484) 321-5900jfickenscher@auxilium.com

wsargent@auxilium.com 


'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
2. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
3. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
4. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
5. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
6. Auxilium Pharmaceuticals to Announce First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10, 2012
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. BioMed Realty Announces 93,000 Square Foot Lease Expansion And Extension With Ironwood Pharmaceuticals At 301 Binney Street
9. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
10. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
11. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... JERUSALEM , April 28, 2016 ... ), a clinical-stage pharmaceutical company focused on the development of ... participate in the upcoming PIONEERS 2016 conference, presented by ... 5, 2016 in New York . ... overview at the conference. Presentation Details:   ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... , ... For those who skip meals occasionally (which is pretty much everyone), ... many new lifestyle diet tips offered by nutritionists Pam Bonney and Priya Lawrence of ... show. Bonny and Lawrence noted that because proper nutrition, including water, provides energy during ...
(Date:4/29/2016)... FL (PRWEB) , ... April 29, 2016 , ... ... will feature Grassland Dairy Products, Inc. in an upcoming episode, airing third quarter ... a century of churning cream into butter, Grassland Dairy Products, located in Greenwood, ...
(Date:4/29/2016)... PLAINSBORO, N.J. (PRWEB) , ... April 29, 2016 ... ... consumer digital and print media enterprise focused entirely on patients with cancer, today ... Mirage, California, was chosen as the 2016 CURE® Extraordinary Healer® for Oncology ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Nike ... long softball camp from July 24th – 27th for girls aged 10-18. All facets ... is held at the beautiful Clark V. Whited Complex, one of the finest softball ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... International Dehydrated ... Seminar on May 3 and 4 at the Doubletree by Hilton Hotel in Oak ... dedicated to marketing and applications technologies for protein ingredients. , At the seminar, IDF™ ...
Breaking Medicine News(10 mins):